Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.52 |
| ▸ | CTSL | P07711 | 2/20 | 0.50 |
| ▸ | CTSS | P25774 | 7/20 | 0.48 |
| ▸ | CTSK | P43235 | 6/20 | 0.48 |
| ▸ | CTSB | P07858 | 4/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CTSG | P08311 | 2/20 | 0.41 |
| ▸ | CMA1 | P23946 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25444807 | 0.88 | ACE (0.60) | ACECTSLCTSSCTSKCTSB | |
| SCHEMBL2349448 | 0.87 | KLK5 (0.55) | ACECTSLCTSSCTSKCTSB | |
| SCHEMBL2349454 | 0.87 | KLK5 (0.55) | ACECTSLCTSSCTSKCTSB | |
| SCHEMBL2352581 | 0.85 | ACE (0.48) | ACECTSLCTSSCTSKCTSB | |
| SCHEMBL638877 | 0.82 | ACE (0.68) | ACECTSLCTSSCTSKCTSB | |
| SCHEMBL495794 | 0.82 | ACE (0.68) | ACECTSLCTSSCTSKCTSB | |
| SCHEMBL495795 | 0.82 | ACE (0.68) | ACECTSLCTSSCTSKCTSB | |
| SCHEMBL2354081 | 0.82 | KLK5 (0.50) | ACECTSLCTSSCTSKCTSB | |
| SCHEMBL17350165 | 0.79 | ACE (0.64) | ACECTSLCTSSCTSKCTSB | |
| SCHEMBL19177404 | 0.78 | CTSS (0.42) | ACECTSLCTSSCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039455-B2 | Macrocyclic compounds useful as BACE inhibitors | NOVARTIS AG (CH) | 2011-10-18 | — | — | US | disclosed |
| US-8008250-B2 | 1-Hydroxy-2-(3-isopropyl-benzylamino)-ethyl]-9,10-dimethyl-2-oxa-9,12-diaza-bicyclo[13.3.1]nonadeca-1(19),15,17-triene-8,11-dione; secretase inhibitor; neurological, vascular disorders, beta-amyloid generation/aggregation; Alzheimer's disease, Down's Syndrome, cognitive impairment, amyloid neuropathies | NOVARTIS AG (CH) | 2011-08-30 | — | — | US | disclosed |
| US-20090029960-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | disclosed |
| US-20080214526-A1 | Macrocyclic Compounds and Compositions Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-09-04 | — | — | US | disclosed |
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-06-05 | — | — | US | disclosed |
| EP-1851208-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2007-11-07 | — | — | EP | disclosed |
| EP-1838680-A2 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006074940-A2 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006074950-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029960-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS | SLC10A2, SLC10A1, ASAH2 | ACE 23/4885CTSL 265/4885CTSS 539/4885 |
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | BACE1, BACE2, APP | ACE 4/4885CTSL 49/4885CTSS 11/4885 |
| US-20080214526-A1 | Macrocyclic Compounds and Compositions Useful as Bace Inhibitors | BACE1, BACE2, APP | ACE 4/4885CTSL 69/4885CTSS 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.